Delayed
Japan Exchange
02:00:00 2024-05-16 EDT
5-day change
1st Jan Change
2,302
JPY
-1.67%
+9.51%
+29.04%
ASKA Pharmaceutical Holdings Co.,Ltd.'s Equity Buyback announced on July 12, 2021, has closed with 300,000 shares, representing 1.06% for ¥316.48 million.
The company closed its plan on March 23, 2022.
Ha Tay Pharmaceutical JSC announced that it has received VND 180.6 billion in funding from ASKA Pharmaceutical Holdings Co.,Ltd.
12-20
CI
ASKA Pharmaceutical Holdings Co.,Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023
23-05-11
CI
Tranche Update on ASKA Pharmaceutical Holdings Co.,Ltd.'s Equity Buyback Plan announced on July 12, 2021.
22-03-24
CI
ASKA Pharmaceutical Holdings Co.,Ltd.'s Equity Buyback announced on July 12, 2021, has closed with 300,000 shares, representing 1.06% for ¥316.48 million.
22-03-22
CI
Tranche Update on ASKA Pharmaceutical Holdings Co.,Ltd.'s Equity Buyback Plan announced on July 12, 2021.
22-01-05
CI
Tranche Update on ASKA Pharmaceutical Holdings Co.,Ltd.'s Equity Buyback Plan announced on July 12, 2021.
21-10-01
CI
ASKA Pharmaceutical Holdings Co.,Ltd. announces an Equity Buyback for 300,000 shares, representing 1.05% for ¥350 million.
21-07-12
CI
ASKA Pharmaceutical Holdings Co.,Ltd. authorizes a Buyback Plan.
21-07-11
CI
ASKA Pharmaceutical Holdings Co., Ltd. acquired 20.04% stake in Japan Glass Industry Co., Ltd.
21-04-22
CI
Ribomic Inc. and ASKA Pharmaceutical Co., Ltd. Announces Execution of A Multi-Year Joint Research and Development Agreement for Drug Discovery Research and Development
21-02-10
CI
ASKA Pharmaceutical Co., Ltd. acquired additional 20% stake in Ha Tay Pharmaceutical JSC.
21-02-03
CI
ASKA Pharmaceutical Co., Ltd. completed the acquisition of 24.9% stake in Ha Tay Pharmaceutical JSC.
21-01-14
CI
Ha Tay Pharmaceutical JSC announced that it has received VND 369.70241 billion in funding from ASKA Pharmaceutical Co., Ltd.
21-01-14
CI
Ha Tay Pharmaceutical JSC announced that it expects to receive VND 369.70241 billion in funding from ASKA Pharmaceutical Co., Ltd. and other investors
20-09-13
CI
ASKA Pharmaceutical Co., Ltd. signed an agreement to acquire 24.9% stake in Ha Tay Pharmaceutical JSC.
20-08-17
CI
Torii and ASKA Enter into Co-Promotion Agreement Concerning Additional Indication of Iron Deficiency Anemia for Riona
20-06-01
CI
ASKA Pharmaceutical Co., Ltd. Announces Dividend for the Year Ended March 31, 2020, Payable on June 26, 2020; Provides Dividend Guidance for the Second Quarter and Year Ended March 31, 2021; Reports Consolidated Earnings Results for the Year Ended March 31, 2020; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2021
20-05-12
CI
ASKA Pharmaceutical Co., Ltd. and Kinopharma, Inc. Enter into Option Agreement for Treatment of Cervical Dysplasia
20-01-14
CI
ASKA Pharmaceutical Co., Ltd. Reports Consolidated Earnings Results for the First Quarter Ended June 2019; Provides Consolidated Earnings Guidance for the Year Ending March 2020
19-08-04
CI
ASKA Pharmaceutical Co., Ltd. and Takeda Pharmaceutical Company Limited Enter into Licensing Agreement for Relugolix in Women's Health Indications
18-05-31
CI
Omnicare Drugs India Pvt. Ltd. and Aska Pharmaceuticals Co. Ltd. Enter into an Agreement to Establish A Joint Venture
18-04-30
CI
ASKA Pharmaceutical and Neopharma Agree to Establish a Joint Venture in India
18-04-19
CI
ASKA Pharmaceutical Co., Ltd. Reports Consolidated Earnings Results for the Six Months Ended September 30, 2017; Provides Consolidated Earnings Guidance for the Ending March 31, 2018
17-11-05
CI
ASKA Pharmaceutical Co., Ltd. Announces Consolidated Earnings Results for the First Quarter Ended June 30, 2017; Provides Earnings Guidance for the Second Quarter Ending September 2017 and for the Full Year Ending March 2018
17-08-06
CI
TesoRx Pharma LLC and ASKA Pharmaceutical Co., Ltd. Announce TSX-011 (Oral Testosterone) Proceeding to Human Studies Following Successful PK Study Results
17-04-27
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
ASKA Pharmaceutical Holdings Co Ltd is a Japan-based company mainly engaged in the pharmaceutical business. The Company mainly operates in two business segments. The Pharmaceutical segment is mainly engaged in the manufacture, purchase and sale of pharmaceutical products. The Others segment is involved in the manufacture of veterinary drugs, the provision of clinical testing services, the outsourcing of testing services, the purchase and sale of medical equipment, as well as the sale of health foods.
More about the company
Last Close Price
2,341
JPY
Average target price
2,733
JPY
Spread / Average Target
+16.76%
Consensus
1st Jan change
Capi.
+29.04% 428M +35.01% 709B +30.71% 595B -2.60% 367B +20.83% 334B +5.69% 289B +14.40% 239B +9.30% 211B -3.44% 203B +10.77% 171B
Other Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
marketscreener.com**derivatives**en**/dynamic-chart/**Premium**Expert**Access**Annual**Monthly**
-40% Limited Time Offer : Our subscriptions help you unlock hidden opportunities.**#000000**/services/solutions/**#fff826**#ff3000**#ffffff**
BENEFIT NOW **0**linear-gradient(180deg, rgba(42,73,76,1) 0%, rgba(28,30,51,1) 53%);**linear-gradient(180deg, rgba(255, 248, 38,1) 0%, rgba(247, 239,1) 53%);**date_fin_hors_prolongation**49**on all our subscriptions**